Literature DB >> 8245869

Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB.

K Berencsi1, R F Rando, C deTaisne, E Paoletti, S A Plotkin, E Gonczol.   

Abstract

A murine model of the cytotoxic T lymphocyte (CTL) response to glycoprotein B (gB) of human cytomegalovirus (HCMV) was developed based on the use of adenovirus (Ad) and vaccinia virus (Vac) recombinants expressing gB. Mice of different major histocompatibility haplotypes [CBA (H-2k), BALB/k (H-2k) and BALB/c (H-2d)] infected with the Ad-gB recombinant developed an Ad-specific CTL response. However, only the H-2k mice developed a significant HCMV gB-specific CTL response, as indicated by the major histocompatibility complex class I-restricted lysis of Vac strain Copenhagen (VacC)-gB recombinant-infected target cells by H-2k mouse immune spleen cells. The VacC-gB recombinant elicited only a weak gB-specific CTL response in these mice, indicating that the observed gB-specific CTL response in mice is dependent on the expression vector used for immunization. The gB-specific cytotoxicity observed in H-2k mice was mediated by the CD8 lymphocyte subset.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8245869     DOI: 10.1099/0022-1317-74-11-2507

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response.

Authors:  Ghislaine Gallez-Hawkins; Maria C Villacres; Xiuli Li; Margaret C Sanborn; Norma A Lomeli; John A Zaia
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

2.  The genotype of mice influences the autoimmune response to spliceosome proteins induced by cytomegalovirus gB immunization.

Authors:  J Lipes; E Skamene; M M Newkirk
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

3.  Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.

Authors:  P W Chen; M Wang; V Bronte; Y Zhai; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

4.  Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.

Authors:  Zhongde Wang; Corinna La Rosa; Rebecca Maas; Heang Ly; John Brewer; Shahram Mekhoubad; Pirouz Daftarian; Jeff Longmate; William J Britt; Don J Diamond
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

5.  Autoimmune response to U1 small nuclear ribonucleoprotein (U1 snRNP) associated with cytomegalovirus infection.

Authors:  M M Newkirk; W J van Venrooij; G S Marshall
Journal:  Arthritis Res       Date:  2001-04-26

6.  Development of two potential diagnostic monoclonal antibodies against human cytomegalovirus glycoprotein B.

Authors:  Fan Jun; Li Minhuan; Ma Yadan; Huang Yaping; Liang Hanying; Hu Jianhua; Yao Hangping; Ma Weihang
Journal:  Braz J Med Biol Res       Date:  2012-05-24       Impact factor: 2.590

Review 7.  Adenoviruses as vaccine vectors.

Authors:  Nia Tatsis; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2004-10       Impact factor: 11.454

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.